You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)獲LBL-007中國境外獨家商業化授權
阿思達克 12-14 12:16
百濟神州(06160.HK)公布,與南京維立志博達成一項授權和合作協定,授予百濟神州LBL-007的全球研發和生產許可,以及中國境外的獨家商業化權利。 LBL-007是一款靶向LAG-3通路的新型抗體。LBL-007用於晚期實體瘤患者的1期臨床試驗資料已經在美國臨床腫瘤學會(ASCO)2021年會上公布。 百濟神州全球研發負責人汪來表示,LBL-007在單藥治療和與其他百濟神州產品管線中的腫瘤免疫藥物聯合上都具有令人期待的組合潛力,其中包括與百濟神州自主研發的抗PD-1抗體藥物替雷利珠單抗的聯合,以提高抗腫瘤活性。 根據協定條款,維立志博將獲得3,000萬美元首付款,並在達成臨床開發、藥政批准和銷售里程碑事件後,有資格獲得至多7.42億美元的總交易額款項,及在授權地區的兩位元數分級銷售特許使用費。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account